Press Releases

Month Year

Month Year

Jun 11, 2025

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Read more
Jun 11, 2025

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Read more
Jun 10, 2025

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

Read more
Jun 4, 2025

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
May 28, 2025

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

Read more
May 21, 2025

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

Read more
May 8, 2025

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

Read more
Apr 29, 2025

Insmed To Present at the BofA Securities 2025 Health Care Conference

Read more
Apr 24, 2025

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

Read more
Apr 23, 2025

New England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation